Login to Your Account

Cerecor Acquires Rights to Merck's Depression Candidate

By Catherine Shaffer
Staff Writer

Monday, April 22, 2013
Cerecor Inc. acquired rights to an NMDA (N-methyl-d-aspartate) antagonist for development in the area of depression from Merck and Co. Inc. The drug, MK-0657, was initially in development at Merck for Parkinson's disease. Increasing evidence in the literature points to NMDA receptors as promising targets in treating depression, including well-known studies with ketamine, an NMDA antagonist.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription